{ "model": { "rank": 6072, "code": "thing-q179996", "model_id": "vr.tr.rs-methadone", "name": "(RS)-methadone", "purpose": "Enable an AI agent to recognise racemic methadone, assess the identity and condition of a represented material, and determine which handling or referral actions its evidence and authorisations support.", "family": "Thing Registry", "category": "Physical world and living systems", "status": "research-draft", "kind": "thing", "plane": "PHY", "domain": "PHY.MAT", "industry": "", "version": "", "url": "/models/thing/q179996/", "tier": 2, "score": 62, "payload": { "layer": "wikidata", "aliases": [ "Dextromethadone", "levomethadone" ], "aliasCount": 2, "merged": 2, "knownIn": 62, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": null, "source": { "dataset": "wikidata", "item": "Q179996", "url": "https://www.wikidata.org/wiki/Q179996", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T11:21:32Z", "providers": [ "Codex", "Grok" ], "missingProviders": [], "pass": 2, "cost": { "grok": { "usd": 0.01211046, "turns": 1, "seconds": 145.3, "error": null }, "codex": { "seconds": 83.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07b97-a2ae-7511-ad4d-29a30d124774\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: (RS)-methadone\nRegistry id: vr.tr.rs-methadone\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none" } } }, "metaModel": { "id": "THING-Q179996", "registryId": "vr.tr.rs-methadone", "name": "(RS)-methadone", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q179996/", "model": { "registry_id": "vr.tr.rs-methadone", "name": "(RS)-methadone", "purpose": "Enable an AI agent to recognise racemic methadone, assess the identity and condition of a represented material, and determine which handling or referral actions its evidence and authorisations support.", "definition": "(RS)-methadone is the racemic 1:1 mixture of the (R)- and (S)-enantiomers of 6-(dimethylamino)-4,4-diphenylheptan-3-one, a synthetic diphenylheptane µ-opioid receptor agonist used clinically almost always as the hydrochloride salt for opioid agonist therapy and as a long-acting analgesic.", "scope_statement": "This PHY / PHY.MAT model owns the substance-level identity of vr.tr.rs-methadone and the evidence needed to assess material represented as that substance; salt forms and formulated products are related representations whose registry boundaries remain to be resolved.", "in_scope": [ "Methadone molecular identity and racemic stereochemical composition", "Evidence distinguishing declared identity from analytically verified identity", "Material form and the basis on which methadone quantity is expressed", "Purity, contamination, storage history and fitness for a stated material use", "Substance-specific handling constraints and links to applicable authorisations" ], "out_of_scope": [ "Patient diagnosis, treatment selection, dosing and clinical monitoring", "Finished medicinal product composition, packaging and marketing authorisation", "Independent models of isolated methadone enantiomers or other chemical substances", "Manufacturing processes and synthesis instructions", "Organisation-wide inventory, prescribing and controlled-substance compliance systems" ], "distinguishing_features": [ "Confirm methadone molecular connectivity against a suitable reference; the molecular formula C21H27NO alone cannot establish identity. Reference: [PubChem methadone](https://pubchem.ncbi.nlm.nih.gov/compound/Methadone).", "Require evidence of an approximately equimolar R/S composition to verify the racemic designation; an unspecified stereochemical label does not establish that composition. Reference: [PubChem racemic methadone record](https://pubchem.ncbi.nlm.nih.gov/substance/178102108).", "Distinguish a racemate from an isolated or enriched enantiomer using an enantioselective measurement with a stated acceptance criterion.", "Resolve whether a material is the free base, a salt or a formulation before comparing identity records or quantities.", "Distinguish identified methadone from a nonspecific opioid screening result by requiring a method capable of discriminating the candidate substances." ], "characteristics": [ { "name": "Identity confidence", "kind": "state", "unit_or_values": "declared only | analytically supported | conflicting | unresolved", "why_it_matters": "Prevents a label or registry match from being treated as proof of the material's identity." }, { "name": "R/S composition", "kind": "measurement", "unit_or_values": "Mole fraction of each enantiomer, uncertainty and method-specific acceptance interval", "why_it_matters": "Determines whether the represented material supports the racemic designation." }, { "name": "Chemical form", "kind": "category", "unit_or_values": "free base | identified salt | form unresolved; record counterion and solvation where established", "why_it_matters": "Controls interpretation of analytical results and substance quantities." }, { "name": "Methadone content", "kind": "measurement", "unit_or_values": "mg/g, mg/mL or mol/L with explicit free-base or salt basis and uncertainty", "why_it_matters": "Supports valid comparisons without confusing material mass with methadone content." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Identified and unidentified components with concentrations, reporting limits and methods", "why_it_matters": "Separates identity confirmation from suitability for the intended use." }, { "name": "Material context", "kind": "relation", "unit_or_values": "Link to bulk lot, reference material, formulation or analytical sample", "why_it_matters": "Determines which specifications and evidence apply to the represented methadone." }, { "name": "Condition assessment", "kind": "state", "unit_or_values": "within documented conditions | excursion recorded | deterioration suspected | unknown", "why_it_matters": "Makes storage uncertainty visible before material is used or transferred." }, { "name": "Action eligibility", "kind": "state", "unit_or_values": "supported | restricted | pending evidence | prohibited under cited authority", "why_it_matters": "Connects a particular proposed action to material fitness and current permissions." } ], "affordances": [ "Reconcile an incoming methadone label with chemical identity and stereochemical evidence.", "Request qualified identity, chiral-composition or impurity testing where evidence is insufficient.", "Compare methadone contents only after resolving chemical form and quantity basis.", "Flag or quarantine material with conflicting identity, failed specifications or unresolved storage excursions.", "Route a proposed transfer, use or disposal through the applicable material and authorisation checks." ] }, "sources": [ { "id": "usp-methadone-hcl", "title": "USP monograph: Methadone Hydrochloride", "url": "", "what_it_supports": "Identity of the hydrochloride salt as the pharmacopoeial substance, and the distinction from the free base." }, { "id": "ph-eur-methadone", "title": "European Pharmacopoeia monograph: Methadone hydrochloride", "url": "", "what_it_supports": "Ph. Eur. identity, assay and impurity control of the racemic hydrochloride." }, { "id": "who-eml", "title": "WHO Model List of Essential Medicines", "url": "", "what_it_supports": "Listing of methadone for opioid dependence and for pain, and its status as an essential medicine." }, { "id": "un-1961", "title": "Single Convention on Narcotic Drugs, 1961", "url": "", "what_it_supports": "International scheduling of methadone as a narcotic drug under INCB control." }, { "id": "fda-label", "title": "Methadone hydrochloride prescribing information (U.S. FDA)", "url": "", "what_it_supports": "Approved uses, boxed warnings (respiratory depression, QT prolongation, accumulation on induction), and formulation types." }, { "id": "samhsa-otp", "title": "Federal guidelines and 42 CFR Part 8 for opioid treatment programs (SAMHSA)", "url": "", "what_it_supports": "U.S. practice of daily supervised oral methadone in certified OTPs." }, { "id": "iuphar-methadone", "title": "IUPHAR/BPS Guide to PHARMACOLOGY: methadone", "url": "", "what_it_supports": "Receptor pharmacology: (R)-enantiomer carries essentially all µ-opioid agonist activity; (S)-enantiomer contributes NMDA antagonism and hERG block." }, { "id": "pubchem-methadone", "title": "PubChem Compound Summary: Methadone", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/4095", "what_it_supports": "CAS 76-99-3, InChIKey, and the racemate as the common chemical record.", "url_status": "live" } ], "structure": { "bundles": [ { "id": "methadone-identity", "name": "Methadone identity", "description": "Establish whether the represented material supports the registered racemic methadone identity.", "rationale": "A methadone name match cannot distinguish molecular identity, stereochemical composition and an unsupported declaration.", "layers": [ { "id": "molecular-identification", "name": "Molecular identification", "description": "Connect the registry identity to discriminating chemical evidence.", "findings": [ { "id": "methadone-connectivity-evidence", "name": "Methadone connectivity evidence", "description": "Record the reference identity, test evidence and competing identities excluded by that evidence.", "questions": [ { "text": "Which structural reference defines methadone for this entry?", "kind": "definition", "id": "methadone-connectivity-evidence-q01" }, { "text": "Which analytical evidence distinguishes methadone from plausible alternative substances in this material?", "kind": "measurement", "id": "methadone-connectivity-evidence-q02" }, { "text": "Does the available result establish methadone identity or only membership in a broader screening category?", "kind": "boundary", "id": "methadone-connectivity-evidence-q03" } ] } ] }, { "id": "racemic-composition", "name": "Racemic composition", "description": "Evaluate the R/S composition independently of total methadone identification.", "findings": [ { "id": "racemate-verification", "name": "Racemate verification", "description": "Record whether the racemic designation is declared or measured, including the acceptance basis.", "questions": [ { "text": "What R and S mole fractions were measured, with what uncertainty?", "kind": "measurement", "id": "racemate-verification-q01" }, { "text": "Which enantioselective method and reference materials support those assignments?", "kind": "provenance", "id": "racemate-verification-q02" }, { "text": "What supported tolerance distinguishes an acceptable racemate from enantiomer-enriched material?", "kind": "boundary", "id": "racemate-verification-q03" } ] } ] } ] }, { "id": "chemical-form-and-content", "name": "Chemical form and content", "description": "Resolve how methadone is physically represented and quantified.", "rationale": "Free-base, salt and formulation quantities cannot be compared without an explicit chemical and measurement basis.", "layers": [ { "id": "form-resolution", "name": "Form resolution", "description": "Identify the chemical form and its relationship to the registry entry.", "findings": [ { "id": "base-salt-and-matrix", "name": "Base, salt and matrix", "description": "Record free-base or salt identity separately from any solvent, excipient or sample matrix.", "questions": [ { "text": "Is the methadone represented as free base or an identified salt, and what evidence establishes this?", "kind": "definition", "id": "base-salt-and-matrix-q01" }, { "text": "Which counterion, solvation state or matrix components affect interpretation of the material?", "kind": "measurement", "id": "base-salt-and-matrix-q02" }, { "text": "Does the registry treat this form as a representation of this entry or as a related registered thing?", "kind": "boundary", "id": "base-salt-and-matrix-q03" } ] } ] }, { "id": "quantity-interpretation", "name": "Quantity interpretation", "description": "Make methadone content comparable across supported material representations.", "findings": [ { "id": "content-basis", "name": "Content basis", "description": "Attach quantity basis, method and uncertainty to each content claim.", "questions": [ { "text": "Is the reported amount expressed as methadone free-base equivalent, a specified salt or total material?", "kind": "definition", "id": "content-basis-q01" }, { "text": "What assay or concentration result applies to this sample, and on what moisture or solvent basis?", "kind": "measurement", "id": "content-basis-q02" }, { "text": "Are chemical form and composition sufficiently established to support the proposed quantity conversion?", "kind": "action", "id": "content-basis-q03" } ] } ] } ] }, { "id": "analytical-quality-and-condition", "name": "Analytical quality and condition", "description": "Assess whether identified racemic methadone meets the requirements of a stated material use.", "rationale": "Correct identity does not establish acceptable impurity levels or continued fitness after storage.", "layers": [ { "id": "purity-and-contamination", "name": "Purity and contamination", "description": "Evaluate methadone content and non-methadone components against an applicable specification.", "findings": [ { "id": "use-specific-quality", "name": "Use-specific quality", "description": "Record which quality requirements have actually been tested and satisfied.", "questions": [ { "text": "Which specification applies to this material's intended laboratory or pharmaceutical use?", "kind": "boundary", "id": "use-specific-quality-q01" }, { "text": "Which impurities, residual solvents or contaminants were measured, and what remained below or outside the method's reporting capability?", "kind": "measurement", "id": "use-specific-quality-q02" }, { "text": "Do the reported results justify acceptance, rejection or further testing under that specification?", "kind": "action", "id": "use-specific-quality-q03" } ] } ] }, { "id": "storage-and-stability", "name": "Storage and stability", "description": "Assess condition using evidence applicable to the actual methadone form and container.", "findings": [ { "id": "condition-validity", "name": "Condition validity", "description": "Connect storage history, observed changes and retest status to a defensible condition assessment.", "questions": [ { "text": "Which documented storage conditions and expiry or retest provisions apply to this form and container?", "kind": "provenance", "id": "condition-validity-q01" }, { "text": "What excursions, container failures or physical changes have been recorded since the last accepted assessment?", "kind": "measurement", "id": "condition-validity-q02" }, { "text": "What evidence is required before material affected by an excursion can return to its intended use?", "kind": "action", "id": "condition-validity-q03" } ] } ] } ] }, { "id": "lot-and-evidence-linkage", "name": "Lot and evidence linkage", "description": "Ensure identity and quality claims apply to the methadone material being assessed.", "rationale": "A certificate for another lot or a methadone assay without chiral analysis cannot establish this material's racemic identity and quality.", "layers": [ { "id": "sample-to-lot-link", "name": "Sample-to-lot link", "description": "Connect the assessed material with the sample and lot represented by its evidence.", "findings": [ { "id": "representative-evidence", "name": "Representative evidence", "description": "Record traceable sample identity and the limits of applying its results to the represented material.", "questions": [ { "text": "Which lot, container and sampled portion does each methadone identity or composition result represent?", "kind": "provenance", "id": "representative-evidence-q01" }, { "text": "Have subdivision, mixing, dilution or repackaging changed the applicability of the original results?", "kind": "boundary", "id": "representative-evidence-q02" } ] } ] }, { "id": "claim-coverage", "name": "Claim coverage", "description": "Separate the evidence supporting molecular identity, racemic composition, content and quality.", "findings": [ { "id": "certificate-coverage-and-conflicts", "name": "Certificate coverage and conflicts", "description": "Expose untested claims and contradictions between labels, certificates and measurements.", "questions": [ { "text": "Which documents or measurements support each of the methadone identity, R/S ratio, content and impurity claims?", "kind": "provenance", "id": "certificate-coverage-and-conflicts-q01" }, { "text": "Where do the label, certificate and independent results disagree or leave a claim unverified?", "kind": "boundary", "id": "certificate-coverage-and-conflicts-q02" }, { "text": "Which claim must remain unresolved until a qualified review or additional test settles the conflict?", "kind": "action", "id": "certificate-coverage-and-conflicts-q03" } ] } ] } ] }, { "id": "hazards-and-permitted-actions", "name": "Hazards and permitted actions", "description": "Connect substance hazards, material fitness and applicable permissions to a proposed action.", "rationale": "Methadone-related hazard information and controlled handling requirements need explicit context before an agent can support a material action.", "layers": [ { "id": "exposure-context", "name": "Exposure context", "description": "Distinguish material-handling assessment from patient-specific clinical decisions.", "findings": [ { "id": "methadone-hazard-applicability", "name": "Methadone hazard applicability", "description": "Record hazards and their evidence context. Methadone hydrochloride medicinal-product labeling identifies life-threatening respiratory depression and QT prolongation; handling decisions require information applicable to the actual material and exposure. Reference: [DailyMed methadone hydrochloride labeling](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d702d32b-98b1-412d-934c-1cd96af4b95a).", "questions": [ { "text": "Which safety information applies to this methadone form, concentration and proposed handling activity?", "kind": "provenance", "id": "methadone-hazard-applicability-q01" }, { "text": "What exposure controls does the applicable safety assessment require for the proposed activity?", "kind": "action", "id": "methadone-hazard-applicability-q02" }, { "text": "Does the proposed decision require referral to a clinical or emergency-response model?", "kind": "boundary", "id": "methadone-hazard-applicability-q03" } ] } ] }, { "id": "action-authorisation", "name": "Action authorisation", "description": "Determine whether a specific action is supported in its jurisdiction and institutional setting.", "findings": [ { "id": "permitted-material-action", "name": "Permitted material action", "description": "Record action-specific authorisation evidence separately from analytical fitness.", "questions": [ { "text": "Which current jurisdictional rules and institutional permissions govern the proposed possession, testing, transfer or disposal?", "kind": "provenance", "id": "permitted-material-action-q01" }, { "text": "Are the proposed actor, recipient, purpose and material form covered by those permissions?", "kind": "boundary", "id": "permitted-material-action-q02" }, { "text": "Should the agent support the action, hold the material pending evidence or refer the decision to the responsible authority?", "kind": "action", "id": "permitted-material-action-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Racemic methadone free base", "Racemic methadone hydrochloride (the usual pharmacopoeial medicinal substance)", "Dilute oral mixture for supervised consumption (commonly 1 mg/mL)", "Oral concentrate (commonly 10 mg/mL)", "Immediate-release tablets or dispersible tablets", "Parenteral (injectable) solution" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "scheme": "Wikidata", "value_or_pattern": "Q179996", "note": "Item for methadone as commonly understood; covers the racemate used in medicine." }, { "scheme": "CAS Registry Number", "value_or_pattern": "76-99-3", "note": "Racemic methadone free base." }, { "scheme": "CAS Registry Number", "value_or_pattern": "1095-90-5", "note": "Racemic methadone hydrochloride, the usual pharmaceutical salt." }, { "scheme": "ATC", "value_or_pattern": "N07BC02", "note": "Methadone as a drug used in opioid dependence." }, { "scheme": "ATC", "value_or_pattern": "N02AC06", "note": "Methadone as an analgesic (diphenylpropylamine derivative)." }, { "scheme": "UNII", "value_or_pattern": "UC6VBE7V1Z", "note": "FDA substance identifier for methadone (free base)." }, { "scheme": "UNII", "value_or_pattern": "229809935B", "note": "FDA substance identifier for methadone hydrochloride." }, { "scheme": "INN", "value_or_pattern": "methadone", "note": "International Nonproprietary Name; the INN denotes the racemate unless an enantiomer prefix is used." }, { "scheme": "DEA ACSCN", "value_or_pattern": "9250", "note": "U.S. controlled-substance code for methadone (Schedule II)." }, { "scheme": "PubChem CID", "value_or_pattern": "4095", "note": "Compound record for methadone." }, { "scheme": "InChIKey", "value_or_pattern": "USSIQXCVUWKGDB-UHFFFAOYSA-N", "note": "Standard InChIKey of the racemate (no stereodescriptor)." }, { "scheme": "DrugBank", "value_or_pattern": "DB00333", "note": "DrugBank accession for methadone." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "USP monograph Methadone Hydrochloride (United States Pharmacopeial Convention)", "European Pharmacopoeia monograph Methadone hydrochloride (EDQM)", "WHO Model List of Essential Medicines: methadone for opioid dependence and pain (World Health Organization)", "Single Convention on Narcotic Drugs, 1961, as a narcotic under international control (United Nations / INCB)", "U.S. Controlled Substances Act Schedule II; DEA ACSCN 9250 (U.S. DEA)", "42 CFR Part 8 certification of opioid treatment programs (SAMHSA, United States)", "U.S. FDA labeling with boxed warnings for respiratory depression, QT prolongation, and fatal accumulation during induction", "Misuse of Drugs Act 1971, Schedule 2 (United Kingdom)" ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Daily supervised oral dosing in opioid treatment programmes as agonist maintenance for heroin, fentanyl and other opioid dependence.", "Take-home oral doses after a patient is judged stable, typically as tablets or measured liquid.", "Around-the-clock analgesia for cancer and other severe chronic pain, especially when shorter-acting opioids have failed or caused incomplete relief.", "Continuation of maintenance (oral or parenteral) during hospital admission or perioperatively so that withdrawal does not interrupt care.", "Use in pregnancy for opioid use disorder, with the neonate then observed for opioid withdrawal.", "Forensic and clinical toxicology as a commonly detected prescription opioid in post-mortem and driving-under-the-influence casework." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "quantity": "Typical oral maintenance dose in opioid agonist therapy", "typical_range": "60-120 (induction often starts much lower, e.g. 10-30)", "unit": "mg/day" }, { "quantity": "Terminal elimination half-life", "typical_range": "8-59 (population mean near 24)", "unit": "h" }, { "quantity": "Oral bioavailability", "typical_range": "70-80 (reported span roughly 36-100)", "unit": "%" }, { "quantity": "Plasma protein binding", "typical_range": "85-90", "unit": "%" }, { "quantity": "Trough plasma concentration cited in TDM practice", "typical_range": "100-400 (poorly correlated with effect; highly individual)", "unit": "µg/L" }, { "quantity": "Enantiomer composition of the racemate", "typical_range": "50:50 (R):(S)", "unit": "mol %" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Fatal respiratory depression during induction or after a missed-dose restart, because accumulation over several days outruns incomplete cross-tolerance.", "Dose-related QT prolongation and torsades de pointes, driven largely by (S)-methadone block of hERG, worsened by high dose, hypokalaemia, and CYP2B6 or CYP3A4 inhibitors.", "Pharmacokinetic interactions (CYP2B6/3A4 inducers and inhibitors, including many antiretrovirals and anticonvulsants) that drop patients into withdrawal or push them into toxicity.", "Additive sedation and respiratory depression with benzodiazepines, alcohol and other CNS depressants.", "Diversion and injection of oral liquids or crushed tablets, with overdose and injection-site harm.", "Neonatal opioid withdrawal after in-utero exposure.", "Hepatic impairment slowing clearance and allowing delayed accumulation.", "Stigma and tightly clinic-bound dispensing that interrupt treatment and precipitate return to unregulated opioids." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "United States, Canada, the United Kingdom and Australia license and dispense the racemate; enantiopure levomethadone is not the routine product.", "Germany, Austria and some neighbouring systems commonly use levomethadone (L-Polamidon) at roughly half the milligram dose of the racemate.", "United Kingdom supervised consumption is classically a green 1 mg/mL oral mixture (DTF), whereas U.S. OTPs often use a 10 mg/mL concentrate diluted at the window.", "France dispenses methadone mainly through specialised centres as syrup or capsules, with a different take-home culture from U.S. OTPs.", "Several health systems have shifted first-line opioid agonist therapy toward buprenorphine, so methadone is encountered more as the second-line or high-tolerance option." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "name": "Levomethadone ((R)-methadone)", "difference": "Enantiopure (R)-isomer; chiral HPLC, specific rotation, or an enantiomer-labelled product distinguishes it. Clinically about twice as potent per milligram at the µ-opioid receptor as the racemate." }, { "name": "Esmethadone / dextromethadone ((S)-methadone)", "difference": "The (S)-enantiomer has negligible µ-opioid maintenance activity and is developed as an NMDA-related agent; chiral analysis or the labelled drug substance separates it from (RS)-methadone." }, { "name": "Buprenorphine", "difference": "Partial µ-agonist with a respiratory ceiling; can precipitate withdrawal in a methadone-maintained patient. Immunoassay plus confirmatory chromatography, and the clinical precipitated-withdrawal test, separate the two." }, { "name": "Morphine", "difference": "Phenanthrene scaffold with a short duration and active glucuronide metabolites; GC-MS/LC-MS identification and the absence of the diphenylheptan-3-one core separate it." }, { "name": "Levacetylmethadol (LAAM)", "difference": "α-acetyl methadol analogue formerly used for thrice-weekly maintenance and withdrawn for arrhythmia; chemical identity (acetylated side chain) and historical product name separate it." }, { "name": "Dipipanone", "difference": "Related diphenylpropylamine opioid (often historically combined with cyclizine); chromatographic identity and the piperidino versus dimethylamino substitution distinguish it." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of (RS)-methadone this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does the authoritative registry scope include methadone salts under vr.tr.rs-methadone, or require links to separate salt entries?", "Does an existing Vercy world model already own this concept, requiring this entry to link to it rather than create another publication?", "Which authoritative specifications and validated chiral methods establish the acceptable R/S interval for each intended material use?", "Which form-specific impurity limits, storage conditions and retest criteria should govern assessments of this entry?", "Which jurisdictions and institutional contexts must the model support, and how will their action-authorisation evidence be kept current?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 37 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "chemical substance or material", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a (RS)-methadone, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to recognise racemic methadone, assess the identity and condition of a represented material, and determine which handling or referral actions its evidence and authorisations support.", "characteristics": { "substance": "material", "origin": "natural", "agency": "inert", "mobility": "varies" }, "whatYouCanDoWithIt": [ "observed and measured", "consumed or used up" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: Dextromethadone, levomethadone.", "2 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 62 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a (RS)-methadone, and on what evidence are they told apart?" ], "whatItIsMadeOf": "matter you can touch", "physicalCharacter": [ "Mobility varies between examples.", "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state", "use it up, and then need more of it" ], "howItIsRecognised": [ "Not recognisable by sight in any reliable way. Appearance varies with grade, form and additives; identification is by label, by documentation, or by assay." ], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "Dextromethadone", "levomethadone" ] } ], "standing": "Described in 62 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 2 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one (RS)-methadone from another, and a (RS)-methadone from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a (RS)-methadone sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a (RS)-methadone from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "form-and-composition", "name": "Form, composition and condition", "description": "What a (RS)-methadone is made of, what shape and size it takes, and what state it is in.", "rationale": "A physical thing can be measured, and a model that cannot record its measurements cannot support any decision that depends on them.", "layers": [ { "id": "form-and-dimensions", "name": "Form and dimensions", "description": "Shape, size, mass and the ranges these take across examples.", "findings": [ { "id": "measurable-dimensions", "name": "Measurable dimensions and their units", "description": "The quantities worth recording and the units they are recorded in.", "questions": [ { "id": "measurable-dimensions-q01", "text": "What identifies and describes the dimensions of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "measurable-dimensions-q02", "text": "Who or what asserted this about the dimensions of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "measurable-dimensions-q03", "text": "What may an agent decide or do once the dimensions of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "material-and-composition", "name": "Material and composition", "description": "Materials, parts and how they are put together.", "findings": [ { "id": "parts-and-materials", "name": "Parts and materials", "description": "What a (RS)-methadone is built from and which parts are replaceable.", "questions": [ { "id": "parts-and-materials-q01", "text": "What identifies and describes the composition of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "parts-and-materials-q02", "text": "Who or what asserted this about the composition of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "parts-and-materials-q03", "text": "What may an agent decide or do once the composition of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "condition-and-integrity", "name": "Condition and integrity", "description": "Wear, damage, health and the difference between working and broken.", "findings": [ { "id": "condition-assessment", "name": "Condition, damage and health", "description": "How the condition of a (RS)-methadone is judged and by whom.", "questions": [ { "id": "condition-assessment-q01", "text": "What identifies and describes the condition of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "condition-assessment-q02", "text": "Who or what asserted this about the condition of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "condition-assessment-q03", "text": "What may an agent decide or do once the condition of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "place-and-movement", "name": "Place and movement", "description": "Where a (RS)-methadone is, how it got there and where it may go (varies).", "rationale": "A thing that can move needs its position recorded with a time, or every later claim about it is about a place it has left.", "layers": [ { "id": "location-and-placement", "name": "Location and placement", "description": "Position, containment and the reference frame the position is given in.", "findings": [ { "id": "position-and-frame", "name": "Position, container and reference frame", "description": "Where a (RS)-methadone is, and what that position is measured against.", "questions": [ { "id": "position-and-frame-q01", "text": "What identifies and describes the location of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "position-and-frame-q02", "text": "Who or what asserted this about the location of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "position-and-frame-q03", "text": "What may an agent decide or do once the location of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "movement-and-transfer", "name": "Movement and transfer", "description": "How a (RS)-methadone is carried, installed or relocated.", "findings": [ { "id": "movement-events", "name": "Movement events and constraints", "description": "What counts as a movement, what records it and what limits it.", "questions": [ { "id": "movement-events-q01", "text": "What identifies and describes the movement of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "movement-events-q02", "text": "Who or what asserted this about the movement of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "movement-events-q03", "text": "What may an agent decide or do once the movement of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a (RS)-methadone passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a (RS)-methadone between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a (RS)-methadone, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a (RS)-methadone is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "use-and-operation", "name": "Use and operation", "description": "What can be done with a (RS)-methadone and what it takes to do it.", "rationale": "An agent that can recognise a thing but not act on it has only half a model.", "layers": [ { "id": "intended-use", "name": "Intended use and function", "description": "What a (RS)-methadone is for, and what it is used for anyway.", "findings": [ { "id": "function-and-purpose", "name": "Function, purpose and misuse", "description": "The function a (RS)-methadone performs and the uses that fall outside it.", "questions": [ { "id": "function-and-purpose-q01", "text": "What identifies and describes the use of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "function-and-purpose-q02", "text": "Who or what asserted this about the use of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "function-and-purpose-q03", "text": "What may an agent decide or do once the use of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "handling-and-procedure", "name": "Handling and procedure", "description": "The steps, skills and tools involved in using a (RS)-methadone.", "findings": [ { "id": "procedures-and-skills", "name": "Procedures, skills and required tools", "description": "What an agent needs before it can act on a (RS)-methadone at all.", "questions": [ { "id": "procedures-and-skills-q01", "text": "What identifies and describes handling a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "procedures-and-skills-q02", "text": "Who or what asserted this about handling a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "procedures-and-skills-q03", "text": "What may an agent decide or do once handling a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "supply-and-consumption", "name": "Supply and consumption", "description": "Quantities, rates and what running out means.", "findings": [ { "id": "consumption-and-stock", "name": "Consumption, stock and replenishment", "description": "How much of a (RS)-methadone there is and how fast it goes.", "questions": [ { "id": "consumption-and-stock-q01", "text": "What identifies and describes the supply of a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "consumption-and-stock-q02", "text": "Who or what asserted this about the supply of a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "consumption-and-stock-q03", "text": "What may an agent decide or do once the supply of a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "composition-and-identity", "name": "Composition, grade and chemical identity", "description": "What (RS)-methadone is made of and how pure the thing in hand is.", "rationale": "Grade decides what a substance may be used for, so a model that records only the name cannot support any decision about use.", "layers": [ { "id": "chemical-identity", "name": "Chemical identity", "description": "Formula, structure and the registry numbers that name it unambiguously.", "findings": [ { "id": "identity-record", "name": "Identity and registry numbers", "description": "What identifies this substance across suppliers and regulators.", "questions": [ { "id": "identity-record-q01", "text": "What formula, structure and registry identifiers name (RS)-methadone unambiguously?", "kind": "definition" }, { "id": "identity-record-q02", "text": "Which related substances share a name in common use but not an identifier?", "kind": "boundary" } ] } ] }, { "id": "grade-and-impurities", "name": "Grade, purity and impurities", "description": "The specification a batch meets and what else is in it.", "findings": [ { "id": "specification", "name": "Specification and assay", "description": "How purity is stated and measured, and which impurities matter.", "questions": [ { "id": "specification-q01", "text": "What grades of (RS)-methadone exist, how is purity assayed, and which impurities are limited?", "kind": "measurement" }, { "id": "specification-q02", "text": "Which use requires which grade, and what happens when a lower grade is substituted?", "kind": "action" } ] } ] } ] }, { "id": "properties-and-behaviour", "name": "Properties and behaviour", "description": "How (RS)-methadone behaves under conditions an agent can measure or change.", "rationale": "Physical constants are the part of a substance model that transfers between contexts, and each needs its unit and its conditions.", "layers": [ { "id": "physical-constants", "name": "Physical constants", "description": "Values that hold for the pure substance, with their conditions.", "findings": [ { "id": "constants-record", "name": "Constants and conditions", "description": "The quantities worth recording and the state they apply in.", "questions": [ { "id": "constants-record-q01", "text": "What are the defining physical constants of (RS)-methadone, in what units and under what conditions?", "kind": "measurement" }, { "id": "constants-record-q02", "text": "Which of these values change with grade or form rather than being fixed?", "kind": "boundary" } ] } ] }, { "id": "stability-and-reactivity", "name": "Stability and reactivity", "description": "What it reacts with, degrades into, and how it is stored.", "findings": [ { "id": "incompatibilities", "name": "Incompatibilities and degradation", "description": "What must not meet it, and what it becomes over time.", "questions": [ { "id": "incompatibilities-q01", "text": "What is (RS)-methadone incompatible with, and what does it degrade into under storage?", "kind": "definition" }, { "id": "incompatibilities-q02", "text": "What storage and handling does that require, and who is competent to do it?", "kind": "action" } ] } ] } ] }, { "id": "hazard-and-regulation", "name": "Hazard classification and regulation", "description": "How (RS)-methadone can harm, and what the law says about holding and moving it.", "rationale": "A substance model without its hazard class and its regulatory identity is unusable in exactly the situations that matter.", "layers": [ { "id": "hazard-class", "name": "Hazard classification", "description": "Classified hazards, exposure limits and protective measures.", "findings": [ { "id": "classified-hazards", "name": "Classified hazards and limits", "description": "The classification, the scheme it belongs to, and the limits set.", "questions": [ { "id": "classified-hazards-q01", "text": "How is (RS)-methadone classified for hazard, under which scheme, and what exposure limits apply?", "kind": "definition" }, { "id": "classified-hazards-q02", "text": "What protection does handling require, and what must an agent refuse to do without it?", "kind": "action" } ] } ] }, { "id": "regulatory-identity", "name": "Regulatory identity and control", "description": "Registration, restriction and transport rules by jurisdiction.", "findings": [ { "id": "controls", "name": "Controls and jurisdiction", "description": "Where it is restricted and what the restriction attaches to.", "questions": [ { "id": "controls-q01", "text": "Which registrations, restrictions or transport rules cover (RS)-methadone, and where?", "kind": "provenance" }, { "id": "controls-q02", "text": "Does the control attach to the substance, its concentration, or its intended use?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a (RS)-methadone came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a (RS)-methadone and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a (RS)-methadone is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a (RS)-methadone, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a (RS)-methadone, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a (RS)-methadone is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 9, "layers": 20, "findings": 22, "questions": 60 } } } }